These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37151099)

  • 1. Locoregional treatment of primary tumor in synchronous metastatic head and neck squamous cell carcinomas.
    Tang E; Schwartz B; Limkin E; Even C; Blanchard P; Haddy N; Gorphe P; Ferrand FR; Tao Y; Nguyen TV
    Acta Oncol; 2023 May; 62(5):465-472. PubMed ID: 37151099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiation therapy on primary tumour of synchronous metastatic head and neck squamous cell carcinomas.
    Tang É; Nguyen TV; Clatot F; Rambeau A; Johnson A; Sun XS; Tao Y; Thariat J
    Cancer Radiother; 2020 Oct; 24(6-7):559-566. PubMed ID: 32753240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of locoregional irradiation in patients with upfront metastatic head and neck squamous cell carcinoma.
    Rambeau A; Bastit V; Thureau S; Thariat J; Moldovan C; Roge M; Babin E; Gery B; Di Fiore F; Florescu C; Clatot F
    Oral Oncol; 2019 Jun; 93():46-51. PubMed ID: 31109695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of primary and adjuvant radiotherapy for cutaneous squamous cell carcinomas of the head-and-neck region in the elderly.
    Haehl E; Rühle A; Klink R; Kalckreuth T; Sprave T; Gkika E; Zamboglou C; Meiß F; Grosu AL; Nicolay NH
    Radiat Oncol; 2021 Jun; 16(1):105. PubMed ID: 34118984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma.
    Chen TH; Pan YY; Lee TL; Wang LW; Tai SK; Chu PY; Lo WL; Wu CH; Yang MH; Chang PM
    BMC Cancer; 2022 Dec; 22(1):1336. PubMed ID: 36539738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of moderate dose escalation for re-irradiation of recurrent or second primary head-and-neck cancer.
    Rühle A; Sprave T; Kalckreuth T; Stoian R; Haehl E; Zamboglou C; Laszig R; Knopf A; Grosu AL; Nicolay NH
    Radiat Oncol; 2020 Apr; 15(1):81. PubMed ID: 32299456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world data of immunotherapy from China in recurrent or metastatic head and neck squamous cell carcinoma.
    Zhang X; Wang P; Chai Y; Zhou X; Li P; Wang X
    Am J Otolaryngol; 2024; 45(1):104065. PubMed ID: 37879241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck.
    Merlano M; Benasso M; Corvò R; Rosso R; Vitale V; Blengio F; Numico G; Margarino G; Bonelli L; Santi L
    J Natl Cancer Inst; 1996 May; 88(9):583-9. PubMed ID: 8609658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Package Time in Node-Positive Cutaneous Head and Neck Squamous Cell Carcinoma.
    Daniels CP; Bressel M; Corry J; Cole A; Chua MS; Tiong A; Hirshoren N; Dixon B; McDowell L
    Pract Radiat Oncol; 2020; 10(1):29-35. PubMed ID: 31606546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent weekly cisplatin and simultaneous integrated boost intensity-modulated radiotherapy of locally advanced squamous cell carcinoma of the head and neck.
    Dubinský P; Jeremic B; Švajdová M; Barilíková G; Matula P; Nadzonová D; Vojtek V
    Klin Onkol; 2022; 35(4):307-314. PubMed ID: 35989088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relevance of the time interval between surgery and adjuvant radio (chemo) therapy in HPV-negative and advanced head and neck carcinoma of unknown primary (CUP).
    Balk M; Rupp R; Mantsopoulos K; Allner M; Grundtner P; Mueller SK; Traxdorf M; Eckstein M; Speer S; Semrau S; Fietkau R; Iro H; Hecht M; Gostian AO
    BMC Cancer; 2021 Nov; 21(1):1236. PubMed ID: 34794411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-escalated re-irradiation improves outcome in locally recurrent head and neck cancer - Results of a large multicenter analysis.
    Roesch J; Oertel M; Wegen S; Trommer M; Schleifenbaum J; Hering D; Mäurer M; Knippen S; Dobiasch S; Waltenberger M; von der Grün J; Medenwald D; Süß C; Hoeck M; Käsmann L; Fleischmann DF; Rühle A; Nicolay NH; Fabian A; Löser A; Heß S; Tamaskovics B; Vinsensia M; Hecht M;
    Radiother Oncol; 2023 Apr; 181():109380. PubMed ID: 36273736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27.
    Lee WR; Berkey B; Marcial V; Fu KK; Cooper JS; Vikram B; Coia LR; Rotman M; Ortiz H
    Int J Radiat Oncol Biol Phys; 1998 Dec; 42(5):1069-75. PubMed ID: 9869231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined modality treatment outcomes for head and neck cancer: comparison of postoperative radiation therapy at academic vs nonacademic medical centers.
    George JR; Yom SS; Wang SJ
    JAMA Otolaryngol Head Neck Surg; 2013 Nov; 139(11):1118-26. PubMed ID: 24051518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage Surgery for Recurrence after Radiotherapy for Squamous Cell Carcinoma of the Head and Neck.
    Elbers JBW; Al-Mamgani A; van den Brekel MWM; Jóźwiak K; de Boer JP; Lohuis PJFM; Willems SM; Verheij M; Zuur CL
    Otolaryngol Head Neck Surg; 2019 Jun; 160(6):1023-1033. PubMed ID: 30526317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multi-institutional comparison of outcomes of immunosuppressed and immunocompetent patients treated with surgery and radiation therapy for cutaneous squamous cell carcinoma of the head and neck.
    Manyam BV; Garsa AA; Chin RI; Reddy CA; Gastman B; Thorstad W; Yom SS; Nussenbaum B; Wang SJ; Vidimos AT; Koyfman SA
    Cancer; 2017 Jun; 123(11):2054-2060. PubMed ID: 28171708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiotherapy for geriatric head-and-neck cancer patients: what is the value of standard treatment in the elderly?
    Haehl E; Rühle A; David H; Kalckreuth T; Sprave T; Stoian R; Becker C; Knopf A; Grosu AL; Nicolay NH
    Radiat Oncol; 2020 Feb; 15(1):31. PubMed ID: 32019576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiotherapy versus Surgery in Early-Stage HPV-Positive Oropharyngeal Cancer.
    Kim DY; Wu HG; Kim JH; Lee JH; Ahn SH; Chung EJ; Eom KY; Jung YH; Jeong WJ; Kwon TK; Kim S; Wee CW
    Cancer Res Treat; 2022 Apr; 54(2):406-416. PubMed ID: 34176249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weekly Cetuximab and Paclitaxel for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    Fushimi C; Baba D; Masubuchi T; Yamazaki M; Kitani Y; Kitajima T; Tanaka J; Hanyu K; Tanaka N; Miura K; Tada Y
    In Vivo; 2020; 34(5):2653-2657. PubMed ID: 32871796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline Neutrophil-to-Lymphocyte Ratio and Glasgow Prognostic Score are Associated with Clinical Outcome in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab.
    Chikuie N; Hamamoto T; Ueda T; Taruya T; Kono T; Furuie H; Ishino T; Takeno S
    Acta Med Okayama; 2021 Jun; 75(3):335-343. PubMed ID: 34176937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.